Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.

Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, Chien-Chung Lin, Pauline Hulo, Christophe Dooms, Jian Fang, Ana Blasco, Dariusz Kowalski, Jorge Salinas, Govind Babu, Tho Lye Mun, Alessandra Bearz, Veerle Surmont, Clarissa Baldotto